Seeger W, Neuhof H, Graubert E, Wolf H, Roka L
Adv Exp Med Biol. 1983;156:533-51.
In a model of isolated rabbit lungs, perfused with isoionic and isooncotic fluid in a recirculating system, the Ca-ionophore A 23187, bradykinin, (kallidin), and eledoisin all evoke a reversible and reproducible increase in pulmonary vascular resistance, partly with biphasic characteristics. Inhibition of thromboxane-synthetase (imidazole), cyclooxygenase (indomethacin) phospholipase activity (mepacrine), and interference with the Ca-calmodulin-complex (trifluoperazine) each suppresses the increase in resistance due to A 23187 or eledoisin completely and the increase due to bradykinin or kallidin to a great extent. Thus thromboxane A2 appears to be the mainly responsible mediator for the increase in vascular resistance after all three stimuli. Moreover, A 23187 and bradykinin cause an increase in vascular permeability that is augmented by indomethacin and diminished by additional lipoxygenase inhibition with BW 352C and which thus can, at least partly, be ascribed to lipoxygenase products of released arachidonic acid. In spite of the described similarities there are marked differences in the relative potencies of A 23187, bradykinin and eledoisin concerning the increase in vascular resistance and the increase in vascular permeability. Therefore, different stimulus transmission-pathways are suggested, having Ca-calmodulin-complex, phospholipase activity and arachidonic acid transformation via cyclooxygenase/thromboxane synthetase respectively via lipoxygenases as common characteristics.
在一个用等离子和等渗液体在循环系统中灌注的离体兔肺模型中,钙离子载体A 23187、缓激肽、(胰激肽)和eledoisin均能引起肺血管阻力可逆且可重复的增加,部分具有双相特征。抑制血栓素合成酶(咪唑)、环氧化酶(吲哚美辛)、磷脂酶活性(米帕林)以及干扰钙调蛋白复合物(三氟拉嗪),均可完全抑制由A 23187或eledoisin引起的阻力增加,并在很大程度上抑制由缓激肽或胰激肽引起的阻力增加。因此,血栓素A2似乎是所有这三种刺激后血管阻力增加的主要介导因子。此外,A 23187和缓激肽会引起血管通透性增加,吲哚美辛可增强这种增加,而BW 352C额外抑制脂氧合酶则会使其减弱,因此这种增加至少部分可归因于释放的花生四烯酸的脂氧合酶产物。尽管存在上述相似之处,但A 23187、缓激肽和eledoisin在增加血管阻力和增加血管通透性方面的相对效力存在显著差异。因此,提示了不同的刺激传导途径,分别以钙调蛋白复合物、磷脂酶活性以及通过环氧化酶/血栓素合成酶或通过脂氧合酶的花生四烯酸转化为共同特征。